P. Escudero

4.1k total citations · 1 hit paper
92 papers, 2.7k citations indexed

About

P. Escudero is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, P. Escudero has authored 92 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in P. Escudero's work include Colorectal Cancer Treatments and Studies (53 papers), Gastric Cancer Management and Outcomes (21 papers) and Colorectal Cancer Surgical Treatments (19 papers). P. Escudero is often cited by papers focused on Colorectal Cancer Treatments and Studies (53 papers), Gastric Cancer Management and Outcomes (21 papers) and Colorectal Cancer Surgical Treatments (19 papers). P. Escudero collaborates with scholars based in Spain, United States and France. P. Escudero's co-authors include Joan Maurel, Antonieta Salud, Vicente Alonso, José Manuel ́Ramírez Rodríguez, A. Trés, Carles Pericay, Jorge Aparicio, Francisco A. García‐Gil, Laura López‐Pingarrón and Dun‐Xian Tan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Surgery.

In The Last Decade

P. Escudero

91 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review

2014 410 citations A. Trés, P. Escudero et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Escudero Spain	23	1.7k	896	792	354	301	92	2.7k
Jan Axelson Sweden	24	712 0.4×	824 0.9×	221 0.3×	652 1.8×	178 0.6×	68	2.3k
M. Kusunoki Japan	27	837 0.5×	778 0.9×	367 0.5×	638 1.8×	49 0.2×	106	2.1k
Dai Shida Japan	28	1.2k 0.7×	800 0.9×	462 0.6×	1.5k 4.1×	29 0.1×	135	3.0k
Christoph Otto Germany	28	382 0.2×	502 0.6×	250 0.3×	869 2.5×	20 0.1×	133	2.8k
Yan Sun China	25	658 0.4×	251 0.3×	597 0.8×	921 2.6×	17 0.1×	91	2.5k
Sundararajah Thevananther United States	26	795 0.5×	707 0.8×	80 0.1×	739 2.1×	26 0.1×	45	2.0k
Jun Ishii Japan	28	373 0.2×	473 0.5×	283 0.4×	700 2.0×	13 0.0×	152	2.4k
Donald Bodenner United States	27	760 0.4×	677 0.8×	362 0.5×	930 2.6×	19 0.1×	62	3.1k
P. Alberto Switzerland	21	635 0.4×	177 0.2×	337 0.4×	341 1.0×	36 0.1×	93	1.4k
Francesca Corti Italy	20	520 0.3×	174 0.2×	241 0.3×	261 0.7×	33 0.1×	65	1.2k

Countries citing papers authored by P. Escudero

Since Specialization

Citations

This map shows the geographic impact of P. Escudero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Escudero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Escudero more than expected).

Fields of papers citing papers by P. Escudero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Escudero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Escudero. The network helps show where P. Escudero may publish in the future.

Co-authorship network of co-authors of P. Escudero

This figure shows the co-authorship network connecting the top 25 collaborators of P. Escudero. A scholar is included among the top collaborators of P. Escudero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Escudero. P. Escudero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vera, Ruth, Elena Mata, Encarnación González‐Flores, et al.. (2020). Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease. 35(4). 739–746. 8 indexed citations

Alonso, Vicente, P. Escudero, Carlos Fernández-Martos, et al.. (2018). Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia. 20(7). 678–686. 9 indexed citations

Carrato, Alfredo, Albert Abad, Bartomeu Massutí, et al.. (2017). First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer. 81. 191–202. 62 indexed citations

Feliú, Jaime, Antonieta Salud, María José Safont, et al.. (2015). Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. PLoS ONE. 10(1). e0116527–e0116527. 34 indexed citations

Sotelo, Miguel J., Javier Sastre, M.L. Maestro, et al.. (2014). Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Annals of Oncology. 26(3). 535–541. 68 indexed citations

Codony‐Servat, Jordi, Xabier García‐Albéniz, Carles Pericay, et al.. (2013). Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Medical Oncology. 30(1). 428–428. 4 indexed citations

Salazar, Ramón, Matilde Navarro, Ferrán Losa, et al.. (2012). Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer. Clinical & Translational Oncology. 14(8). 592–598. 4 indexed citations

Rodríguez, José Manuel ́Ramírez, et al.. (2011). Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results. International Journal of Colorectal Disease. 26(4). 437–443. 41 indexed citations

Gallego, Rosa, Xabier García‐Albéniz, Vicente Alonso, et al.. (2011). Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. Cancer Biology & Therapy. 11(2). 177–183. 7 indexed citations

10.

Alonso, Vicente, Carles Pericay, P. Escudero, et al.. (2010). Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer. Chemotherapy. 56(2). 142–146. 18 indexed citations

11.

Bennouna, Jaafar, István Láng, Manuel Valladares‐Ayerbes, et al.. (2010). A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Investigational New Drugs. 29(5). 1021–1028. 117 indexed citations

12.

Rodríguez, José Manuel ́Ramírez, et al.. (2009). Local Full-Thickness Excision as First Line Treatment for Sessile Rectal Adenomas. Annals of Surgery. 249(2). 225–228. 40 indexed citations

13.

López–Pousa, Antonio, Javier Martín‐Broto, Joaquín Montalar, et al.. (2006). Phase II Trial of Doxorubicin Plus Escalated High‐Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma. 2006(1). 26986–26986. 4 indexed citations

14.

Feliú, Jaime, Antonieta Salud, P. Escudero, et al.. (2006). XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. British Journal of Cancer. 94(7). 969–975. 80 indexed citations

15.

Poveda, Andrés, Antonio López–Pousa, Javier Martín‐Broto, et al.. (2005). Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ‐C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma. 9(3-4). 127–132. 28 indexed citations

16.

Cassinello, Javier, P. Escudero, Antonieta Salud, et al.. (2003). Activity and Safety of Oxaliplatin with Weekly 5-Fluorouracil Bolus and Low-Dose Leucovorin as First-Line Treatment for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 3(2). 108–112. 3 indexed citations

17.

Feliú, Jaime, J. R. Mel, Carlos Camps, et al.. (2002). Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. European Journal of Cancer. 38(9). 1204–1211. 22 indexed citations

18.

Marti, Juan Luis Gomez, José Mayordomo, Dolores Isla, et al.. (2001). Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Annals of Oncology. 12(8). 1061–1065. 15 indexed citations

19.

Buesa, J., Antonio López–Pousa, Javier Martín‐Broto, et al.. (1998). Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology. 9(8). 871–876. 50 indexed citations

20.

Buesa, J., J. Fra, A. Antón, et al.. (1998). Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology. 9(7). 783–785. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact